The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Induction Chemotherapy with MVP in Patients with Stage IIIa (T1-3, N2, M0) Unresectable Non Small Cell Lung Cancer (NSCLC): The Toronto Experience.
 
Thomas DeLeon
No Relationships to Disclose
 
Marcela Salomao
No Relationships to Disclose
 
Bashar A. Aqel
No Relationships to Disclose
 
Mohamad B. Sonbol
No Relationships to Disclose
 
Alan Haruo Bryce
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun BioPharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene